{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:02:16Z","timestamp":1793898136191,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,15]],"date-time":"2012-12-15T00:00:00Z","timestamp":1355529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s10549-012-2368-y","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T06:10:49Z","timestamp":1355465449000},"page":"349-357","source":"Crossref","is-referenced-by-count":150,"title":["Trastuzumab administration during pregnancy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"137","author":[{"given":"Flora","family":"Zagouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros N.","family":"Sergentanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimosthenis","family":"Chrysikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos A.","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanassios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,15]]},"reference":[{"key":"2368_CR1","doi-asserted-by":"crossref","first-page":"v266","DOI":"10.1093\/annonc\/mdq198","volume":"21","author":"G Pentheroudakis","year":"2010","unstructured":"Pentheroudakis G, Orecchia R, Hoekstra HJ et al (2010) Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v266\u2013v273","journal-title":"Ann Oncol"},{"key":"2368_CR2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/annonc\/mdm460","volume":"19","author":"O Mir","year":"2008","unstructured":"Mir O, Berveiller P, Ropert S et al (2008) Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 19:607\u2013613","journal-title":"Ann Oncol"},{"key":"2368_CR3","unstructured":"Howlader N, Noone AM, Krapcho M, et al (2011) SEER cancer statistics review, 1975\u20132008. National Cancer Institute. Bethesda. http:\/\/seer.cancer.gov\/csr\/1975_2008\/ , based on November 2010 SEER data submission, posted to the SEER web site"},{"key":"2368_CR4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","volume":"12","author":"L Gianni","year":"2011","unstructured":"Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1\u00a0year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236\u2013244","journal-title":"Lancet Oncol"},{"key":"2368_CR5","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"2368_CR6","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351\u20133357","journal-title":"J Clin Oncol"},{"key":"2368_CR7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","volume":"29","author":"V Valero","year":"2011","unstructured":"Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149\u2013156","journal-title":"J Clin Oncol"},{"key":"2368_CR8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","volume":"29","author":"M Andersson","year":"2011","unstructured":"Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29:264\u2013271","journal-title":"J Clin Oncol"},{"key":"2368_CR9","unstructured":"NCCN Clinical Practice Guidelines in Oncology (2012) Breast cancer, version 2.2012. www.nccn.com"},{"key":"2368_CR10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1586\/eci.10.77","volume":"6","author":"HA Azim Jr","year":"2010","unstructured":"Azim HA Jr, Azim H, Peccatori FA (2010) Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 6:821\u2013826","journal-title":"Expert Rev Clin Immunol"},{"key":"2368_CR11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.24835","volume":"116","author":"ME Abusief","year":"2010","unstructured":"Abusief ME, Missmer SA, Ginsburg ES et al (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116:791\u2013798","journal-title":"Cancer"},{"key":"2368_CR12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1\u2013e34","journal-title":"J Clin Epidemiol"},{"key":"2368_CR13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000335202","volume":"6","author":"I Gottschalk","year":"2011","unstructured":"Gottschalk I, Berg C, Harbeck N et al (2011) Fetal renal insufficiency following trastuzumab treatment for breast cancer in pregnancy: case report und review of the current literature. Breast Care (Basel) 6:475\u2013478","journal-title":"Breast Care (Basel)"},{"key":"2368_CR14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1447-0756.2011.01745.x","volume":"38","author":"S El-Safadi","year":"2012","unstructured":"El-Safadi S, Wuesten O, Muenstedt K (2012) Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. J Obstet Gynaecol Res 38:589\u2013592","journal-title":"J Obstet Gynecol Res"},{"key":"2368_CR15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1479-828X.2011.01314.x","volume":"51","author":"CL Mandrawa","year":"2011","unstructured":"Mandrawa CL, Stewart J, Fabinyi GC et al (2011) A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust N Z J Obstet Gynaecol 51:372\u2013376","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2368_CR16","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1186\/1757-1626-2-9329","volume":"2","author":"MJ Goodyer","year":"2009","unstructured":"Goodyer MJ, Ismail JR, O\u2019Reilly SP et al (2009) Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J 2:9329","journal-title":"Cases J"},{"key":"2368_CR17","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.ajog.2009.02.017","volume":"201","author":"JM Beale","year":"2009","unstructured":"Beale JM, Tuohy J, McDowell SJ (2009) Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol 201:e13\u2013e14","journal-title":"Am J Obstet Gynecol"},{"key":"2368_CR18","doi-asserted-by":"crossref","unstructured":"Weber-Schoendorfer C, Schaefer C (2008) Trastuzumab exposure during pregnancy. Reprod Toxicol 25:390\u2013391; author reply 392","DOI":"10.1016\/j.reprotox.2008.02.002"},{"key":"2368_CR19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.2008.16.0309","volume":"26","author":"S Pant","year":"2008","unstructured":"Pant S, Landon MB, Blumenfeld M et al (2008) Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 26:1567\u20131569","journal-title":"J Clin Oncol"},{"key":"2368_CR20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/annonc\/mdm542","volume":"19","author":"ID Witzel","year":"2008","unstructured":"Witzel ID, M\u00fcller V, Harps E et al (2008) Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 19:191\u2013192","journal-title":"Ann Oncol"},{"key":"2368_CR21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/01.AOG.0000267133.65430.44","volume":"110","author":"R Sekar","year":"2007","unstructured":"Sekar R, Stone PR (2007) Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 110:507\u2013510","journal-title":"Obstet Gynecol"},{"key":"2368_CR22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.reprotox.2007.02.003","volume":"23","author":"A Shrim","year":"2007","unstructured":"Shrim A, Garcia-Bournissen F, Maxwell C et al (2007) Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy- Case report and updated literature review. Reprod Toxicol 23:611\u2013613","journal-title":"Reprod Toxicol"},{"key":"2368_CR23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1470-2045(06)71014-2","volume":"8","author":"AA Bader","year":"2007","unstructured":"Bader AA, Schlembach D, Tamussino KF et al (2007) Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 8:79\u201381","journal-title":"Lancet Oncol"},{"key":"2368_CR24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2005.04.6607","volume":"24","author":"AM Waterston","year":"2006","unstructured":"Waterston AM, Graham J (2006) Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 24:321\u2013322","journal-title":"J Clin Oncol"},{"key":"2368_CR25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3816\/CBC.2005.n.040","volume":"6","author":"MA Fanale","year":"2005","unstructured":"Fanale MA, Uyei AR, Theriault RL et al (2005) Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6:354\u2013356","journal-title":"Clin Breast Cancer"},{"key":"2368_CR26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/01.AOG.0000141570.31218.2b","volume":"105","author":"WJ Watson","year":"2005","unstructured":"Watson WJ (2005) Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 105:642\u2013643","journal-title":"Obstet Gynecol"},{"key":"2368_CR27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrclinonc.2009.48","volume":"6","author":"HA Azim Jr","year":"2009","unstructured":"Azim HA Jr, Peccatori FA, Liptrott SJ et al (2009) Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol 6:367\u2013370","journal-title":"Nat Rev Clin Oncol"},{"key":"2368_CR28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/01443610802643774","volume":"29","author":"Q Warraich","year":"2009","unstructured":"Warraich Q, Smith N (2009) Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J Obstet Gynaecol 29:147\u2013148","journal-title":"J Obstet Gynaecol"},{"key":"2368_CR29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1258\/jrsm.2009.090260","volume":"103","author":"NJ Roberts","year":"2010","unstructured":"Roberts NJ, Auld BJ (2010) Trastuzamab (Herceptin)-related cardiotoxicity in pregnancy. J R Soc Med 103:157\u2013159","journal-title":"J R Soc Med"},{"key":"2368_CR30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2009.11.007","volume":"36","author":"HA Azim Jr","year":"2010","unstructured":"Azim HA Jr, Peccatori FA, Pavlidis N (2010) Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat Rev 36:101\u2013109","journal-title":"Cancer Treat Rev"},{"key":"2368_CR31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000341351","volume":"83","author":"F Zagouri","year":"2012","unstructured":"Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology 83:234\u2013238","journal-title":"Oncology"},{"key":"2368_CR32","doi-asserted-by":"crossref","unstructured":"Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for breast cancer during pregnancy: a systematic review. Clin Breast Cancer [Epub Ahead of print]","DOI":"10.1016\/j.clbc.2012.09.014"},{"key":"2368_CR33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/bdrb.20201","volume":"86","author":"N Pentsuk","year":"2009","unstructured":"Pentsuk N, van der Laan JW (2009) An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86:328\u2013344","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"2368_CR34","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1016\/S0264-410X(03)00333-5","volume":"21","author":"A Malek","year":"2003","unstructured":"Malek A (2003) Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine 21:3362\u20133364","journal-title":"Vaccine"},{"key":"2368_CR35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00003081-199706000-00009","volume":"40","author":"SJ Kilpatrick","year":"1997","unstructured":"Kilpatrick SJ (1997) Therapeutic interventions for oligohydramnios: amnioinfusion and maternal hydration. Clin Obstet Gynecol 40:328\u2013336","journal-title":"Clin Obstet Gynecol"},{"key":"2368_CR36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1084-2756(03)00022-8","volume":"8","author":"T Vanderheyden","year":"2003","unstructured":"Vanderheyden T, Kumar S, Fisk NM (2003) Fetal renal impairment. Semin Neonatol 8:279\u2013289","journal-title":"Semin Neonatol"},{"key":"2368_CR37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/BF00852567","volume":"7","author":"PR Goodyer","year":"1993","unstructured":"Goodyer PR, Cybulsky A, Goodyer C (1993) Expression of the epidermal growth factor receptor in fetal kidney. Pediatr Nephrol 7:612\u2013615","journal-title":"Pediatr Nephrol"},{"key":"2368_CR38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/1043-4666(94)90068-X","volume":"6","author":"PP Jokhi","year":"1994","unstructured":"Jokhi PP, King A, Loke YW (1994) Reciprocal expression of epidermal growth factor receptor (EGF-R) and c-erbB2 by non-invasive and invasive human trophoblast populations. Cytokine 6:433\u2013442","journal-title":"Cytokine"},{"key":"2368_CR39","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","volume":"378","author":"KF Lee","year":"1995","unstructured":"Lee KF, Simon H, Chen H et al (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394\u2013398","journal-title":"Nature"},{"key":"2368_CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-012-1996-6","volume":"133","author":"HA Azim Jr","year":"2012","unstructured":"Azim HA Jr, Metzger-Filho O, de Azambuja E et al (2012) Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01\u201301). Breast Cancer Res Treat 133:387\u2013391","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2368-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2368-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2368-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:47:10Z","timestamp":1559234830000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2368-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,15]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["2368"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2368-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,15]]}}}